<?xml version="1.0" encoding="UTF-8"?>
<p id="par0220">In addition to these uses, the HSV-1 TK molecule has been extensively exploited as a reporter for SPECT or PET imaging of malignancies and the assessment of gene therapy (
 <xref rid="bib0270" ref-type="bibr">Green et al., 2004</xref>, 
 <xref rid="bib0400" ref-type="bibr">Miyagawa et al., 2008</xref>, 
 <xref rid="bib0475" ref-type="bibr">Serganova et al., 2007</xref>). In a novel therapeutic approach, HSV itself is now being harnessed to kill malignant cells, and its distribution and replication are being monitored by PET imaging, using 
 <sup>124</sup>I-FIAU as the tracer (
 <xref rid="bib0025" ref-type="bibr">Bennett et al., 2001</xref>, 
 <xref rid="bib0335" ref-type="bibr">Kuruppu et al., 2007</xref>). It has recently been shown that treatment of herpesvirus-induced cancers, such as Burkitt's lymphoma, with the anti-cancer drug bortezomib triggers expression of the viral TK, making it possible not only for the tumors to be visualized by PET, but potentially treated with ganciclovir (
 <xref rid="bib0240" ref-type="bibr">Fu et al., 2007</xref>).
</p>
